Analyst Rating Update on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN) : The consensus on Regeneron Pharmaceuticals (REGN) based on 20 analyst recommendation on the company stock is 2.45, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Regeneron Pharmaceuticals (REGN) : The highest level Regeneron Pharmaceuticals (REGN) is projected to reach is $668 for the short term and the lowest estimate is at $325. The consolidated price target from 18 rating analysts who initiate coverage on the stock is $487.5 and the possibility the share price can swing is $82.33.

For the current week, the company shares have a recommendation consensus of Buy.


Regeneron Pharmaceuticals (NASDAQ:REGN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $434.70 and $433.56 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $442.29. The buying momentum continued till the end and the stock did not give up its gains. It closed at $441.37, notching a gain of 1.49% for the day. The total traded volume was 1,102,410 . The stock had closed at $434.90 on the previous day.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *